HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, Volume 2, February 2016 Biomedical Research Governance       » Tissue banking in Singapore — An Evolving Enterprise       » China Recognizes Prominent Scientists and Stresses on Innovation       » NUS Researchers Uncover Potent Parasite-killing Mechanism of Nobel Prize-Winning Anti-Malarial Drug       » A New Water Robot "Born" to Detect Water Quality       » Probing the Mystery of How Cancer Cells Die       » Researchers Find Link between Processed Foods and Autoimmune Diseases       » Unravelling the Genetics of Pregnancy and Heart Failure      
BIOBOARD - INDIA
Indian court's Novartis ruling keeps door to cheap drugs open
The Swiss pharmaceutical company Novartis has lost its seven-year court battle to patent the cancer drug Glivec in India, where generic versions of the medicine provide life-saving drugs to thousands of people.

Novartis wanted exclusive rights to manufacture the drug on the grounds that a new substance had been used in its production. But the Indian Supreme Court in Delhi ruled that the small changes to the drug were not worthy of a patent: the drug had "failed in both the tests of invention and patentability", it said.

The ruling is a victory for Indian generic drug companies and will enable some 300,000 patients in the country and many more in other developing countries to access cheaper generic versions of Glivec.

India is widely known as the 'world's pharmacy', because it supplies cheap, generic versions of medicines to many countries across the developing world.

Prices of Indian generic versions of Glivec, which is mainly used to treat leukaemia, are many times lower than those of the branded drug.

Novartis was contesting the rejection of its 2005 patent application by the Indian Patent Office and the Intellectual Property Appellate Board to patent imatinib, a salt form of imatinib mesylate, the drug marketed as Glivec.

The court ruled that as imatinib is only a modification of a known molecule, and since it does not offer improved therapeutic efficacy, it is not patentable, according to the 2005 Indian Patents Act.

Section 3(d) of the 2005 act stipulates that an innovation constituting "the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance" cannot be patented.

Generic versions of Glivec are currently marketed by Indian companies like Ranbaxy, Natco Pharma and Cipla.

Natco Pharma, one of the appellants in the Novartis case, says the judgment is a victory for both cancer patients and the Indian government.

Madineedi Adinarayana, Natco's general manager, tells SciDev.Net that the judgment is a victory for the entire generic pharmaceutical industry and for section 3(d) of the patents act.

"It is a feature unique to Indian law, and many countries like China and South Korea plan to amend their laws to incorporate this provision," he says. "We are offering Glivec to Indian patients for 9,600 Indian rupees [US$177] a month while Novartis charges 110,000 rupees [US$2,270] a month."

Adinarayana says the Glivec judgement will ensure that drugs are accessible to the poor.

Leena Menghaney, India manager for Médecins Sans Frontières' Access Campaign, tells SciDev.Net that the ruling "appears to be the best outcome for patients in developing countries as fewer patents will be granted on existing medicines".

"Novartis's attacks on the elements of India's patent law that protect public health have failed," she says.

"The Supreme Court's decision prevents companies from abusing the patent system … [and] confirms that all patent offices in India have to use this interpretation and the law is now clear and must be strictly applied," she adds.

But Novartis has said the judgment will hinder research on new drugs and discourage innovation.

"We strongly believe that original innovation should be recognized in patents to encourage investment in medical innovation especially for unmet medical needs," Ranjit Shahani, vice chairman and managing director of Novartis India, said in a press statement.

M Sreelata
Source: Science Development Network

Click here for the complete issue.

NEWS CRUNCH  
news Singapore Researchers Develop World'S First High-Throughput Imaging Platform for Predicting Kidney Toxicity
news Collaboration is Cure for Better Global Health Outcomes, UK-India Experts Say
news EmTech Asia Opens: Features 50 speakers on innovation and emerging technologies
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Primates in Biomedical Research
COLUMNS  
\
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Cancerology / Oncology
May:
Guest Editorial - Antibody Informatics In Japan
June:
Medical Devices and Technology
July:
Water Technology
August:
Occupational Health
September:
Olympics: Evolution of Sports
October:
Respiratory: Seasonal flu viruses
November:
Tobacco Smoking
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy